Compare MBIN & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBIN | AUPH |
|---|---|---|
| Founded | 1990 | 1993 |
| Country | United States | Canada |
| Employees | 735 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | N/A | 2014 |
| Metric | MBIN | AUPH |
|---|---|---|
| Price | $49.11 | $16.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $43.67 | $17.25 |
| AVG Volume (30 Days) | 89.2K | ★ 1.1M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | $31.76 | $17.54 |
| Revenue Next Year | $3.73 | $15.74 |
| P/E Ratio | ★ $12.29 | $65.72 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $28.75 | $7.29 |
| 52 Week High | $51.00 | $16.88 |
| Indicator | MBIN | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 57.40 | 60.55 |
| Support Level | $44.97 | $14.60 |
| Resistance Level | $50.26 | $16.88 |
| Average True Range (ATR) | 1.43 | 0.52 |
| MACD | 0.13 | 0.07 |
| Stochastic Oscillator | 65.52 | 86.17 |
Merchants Bancorp is a United States-based bank holding company operating multiple lines of business focused on FHA multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. Its segments include Multi-family Mortgage Banking, which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing, which offers mortgage warehouse financing, commercial loans and deposit services; and the Banking segment, which generates maximum revenue and provides portfolio lending for multi-family and healthcare facility loans, residential mortgage banking, agricultural lending, SBA lending and community banking.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.